Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use

PHASE4CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

July 31, 2009

Conditions
Tobacco Use Cessation
Interventions
DRUG

Varenicline Tartrate

Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.

DRUG

Placebo

Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.

Trial Locations (16)

2317

Pfizer Investigational Site, Hamar

3515

Pfizer Investigational Site, Hønefoss

4042

Pfizer Investigational Site, Hafrsfjord

5235

Pfizer Investigational Site, Rådal

6900

Pfizer Investigational Site, Florø

7034

Pfizer Investigational Site, Trondheim

0407

Pfizer Investigational Site, Oslo

413 45

Pfizer Investigational Site, Gothenburg

254 52

Pfizer Investigational Site, Helsingborg

177 31

Pfizer Investigational Site, Jarfalla

652 24,

Pfizer Investigational Site, Karlstad

701 85

Pfizer Investigational Site, Örebro

151 87

Pfizer Investigational Site, Södertälje

118 91

Pfizer Investigational Site, Stockholm

852 31

Pfizer Investigational Site, Sundsvall

901 85

Pfizer Investigational Site, Umeå

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00717093 - Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use | Biotech Hunter | Biotech Hunter